TG Therapeutics (TGTX) UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with R/R Marginal Zone Lymphoma Met Primary Endpoint
Tweet Send to a Friend
TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
